<PAGE>
EXHIBIT 10.8
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
June 4, 2002
Re: ADVANCE MI Study
Gentlemen:
As you are aware, Schering Corporation ("Schering") and
Millennium
Pharmaceuticals, Inc. ("Millennium") are
considering undertaking a Study (as
defined below) under the terms of the
Collaboration Agreement, dated April 10,
1995, as amended (the "Agreement").
This letter confirms that Schering has agreed in principle to pay
the
lesser of (i) $[**] or (ii) [**] percent
([**]%) of the cost of the ADVANCE MI
clinical study that has been proposed by
Millennium to the FDA at the meeting on
May 22, 2002 (the protocol for which is
attached to this letter and made a part
hereof). Following the FDA meeting,
Schering and Millennium will promptly meet
to review all FDA requested changes.
Schering and Millennium will in good faith
discuss and seek agreement to include such
changes to the study as may be
necessary from a clinical safety standpoint
or as otherwise agreed. Both Parties
will use good faith efforts to have the
ADVANCE-MI protocol finalized and issued
(the "Study") no more than ten (10)
business days after the FDA meeting.
Agreement by Schering under this letter agreement to fund the Study
is
made on
